Scholarlink

Background <p>Sepsis therapy faces a critical paradox: Gasdermin D (GSDMD)-mediated neutrophil extracellular traps (NETs) exert protective host defense early but drive tissue injury late. Defining the temporal dynamics of intervening in this axis is central to overcoming therapeutic limitations.</p> Methods <p>In a cecal ligation and puncture (CLP) model recapitulating human sepsis progression, disulfiram (DSF, 80&#xa0;mg/kg) or vehicle was administered intraperitoneally at 0&#xa0;h, 4&#xa0;h, or 8&#xa0;h postoperatively. A comprehensive multidimensional analysis assessed survival, bacterial burden (lung/blood/peritoneum), cytokines (TNF-α/IL-6/IL-1β), lung injury (histopathology/wet-dry ratio/Evans Blue extravasation), GSDMD activation, NET formation (Sytox-green/CitH3-MPO), and neutrophil function (LY6G<sup>+</sup> infiltration/viability).</p> Results <p>Immediate DSF (0&#xa0;h) proved detrimental, exacerbating bacterial dissemination (lung↑, <i>P</i> = 0.0036; blood↑, <i>P</i> = 0.0488), hyperinflammation (TNF-α↑, <i>P</i> = 0.0165; IL-6↑, <i>P</i> = 0.0140), and shortening survival (<i>P</i> = 0.0417). Conversely, delayed DSF (8&#xa0;h) yielded significant benefits, reducing bacterial load (lung↓, <i>P</i> = 0.0002; blood↓, <i>P</i> = 0.0309), suppressing cytokines (TNF-α↓, <i>P</i> = 0.0121; IL-6↓, <i>P</i> = 0.0022), and extending survival (<i>P</i> &lt; 0.0001). Mechanistically, while DSF consistently inhibited GSDMD cleavage and NETs, only delayed intervention attenuated NET-driven microthrombosis, reduced LY6G<sup>+</sup> infiltration (<i>P</i> = 0.0112), and enhanced neutrophil viability (<i>P</i> = 0.0007).</p> Conclusion <p>Targeting the GSDMD–NETs axis is fundamentally timing-dependent. Immediate inhibition disrupts essential host defenses, whereas delayed treatment (8&#xa0;h post-CLP) preserves bacterial clearance, reduces lung injury, and improves survival. By establishing a therapeutic window, our study provides the first systematic evidence that the success of disulfiram in sepsis depends on when it is administered, offering a clinically actionable framework to guide future biomarker-driven trials and bedside decision-making in critical care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Delayed disulfiram targeting GSDMD-NETs axis rescues sepsis by limiting bacterial spread and lung injury

  • 期刊论文

  • 发表日期：

    2026年2月18日

查看全文
  • Xiaoxi Shan,
  • Zhishu Li,
  • Lixia Dong

摘要

Background

Sepsis therapy faces a critical paradox: Gasdermin D (GSDMD)-mediated neutrophil extracellular traps (NETs) exert protective host defense early but drive tissue injury late. Defining the temporal dynamics of intervening in this axis is central to overcoming therapeutic limitations.

Methods

In a cecal ligation and puncture (CLP) model recapitulating human sepsis progression, disulfiram (DSF, 80 mg/kg) or vehicle was administered intraperitoneally at 0 h, 4 h, or 8 h postoperatively. A comprehensive multidimensional analysis assessed survival, bacterial burden (lung/blood/peritoneum), cytokines (TNF-α/IL-6/IL-1β), lung injury (histopathology/wet-dry ratio/Evans Blue extravasation), GSDMD activation, NET formation (Sytox-green/CitH3-MPO), and neutrophil function (LY6G+ infiltration/viability).

Results

Immediate DSF (0 h) proved detrimental, exacerbating bacterial dissemination (lung↑, P = 0.0036; blood↑, P = 0.0488), hyperinflammation (TNF-α↑, P = 0.0165; IL-6↑, P = 0.0140), and shortening survival (P = 0.0417). Conversely, delayed DSF (8 h) yielded significant benefits, reducing bacterial load (lung↓, P = 0.0002; blood↓, P = 0.0309), suppressing cytokines (TNF-α↓, P = 0.0121; IL-6↓, P = 0.0022), and extending survival (P < 0.0001). Mechanistically, while DSF consistently inhibited GSDMD cleavage and NETs, only delayed intervention attenuated NET-driven microthrombosis, reduced LY6G+ infiltration (P = 0.0112), and enhanced neutrophil viability (P = 0.0007).

Conclusion

Targeting the GSDMD–NETs axis is fundamentally timing-dependent. Immediate inhibition disrupts essential host defenses, whereas delayed treatment (8 h post-CLP) preserves bacterial clearance, reduces lung injury, and improves survival. By establishing a therapeutic window, our study provides the first systematic evidence that the success of disulfiram in sepsis depends on when it is administered, offering a clinically actionable framework to guide future biomarker-driven trials and bedside decision-making in critical care.